Austrianni has unrestricted access to a powerful antibody discovery platform developed by the California company Trianni.  This platform features a full complement of human antibody variable domains that undergo natural V(D)J recombination and somatic hypermutation.  Austrianni will exploit this platform to isolate fully human antibody therapeutics specific for use in the treatment of tuberculosis.  Drawing on its extensive in-house genetics and immunological expertise, the company is also establishing advanced genetic models and assay systems to accelerate its preclinical testing program and to allow for rapid progress toward clinical testing.